Last reviewed · How we verify

Mirabegron 50 MG

Hasanuddin University · FDA-approved active Small molecule Quality 5/100

Mirabegron 50 MG is a Small molecule drug developed by Hasanuddin University. It is currently FDA-approved. Also known as: Tamsulosin 0.4 mg, Placebo, Myrbertiq, Hibero.

At a glance

Generic nameMirabegron 50 MG
Also known asTamsulosin 0.4 mg, Placebo, Myrbertiq, Hibero, Myrbetriq
SponsorHasanuddin University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mirabegron 50 MG

What is Mirabegron 50 MG?

Mirabegron 50 MG is a Small molecule drug developed by Hasanuddin University.

Who makes Mirabegron 50 MG?

Mirabegron 50 MG is developed and marketed by Hasanuddin University (see full Hasanuddin University pipeline at /company/hasanuddin-university).

Is Mirabegron 50 MG also known as anything else?

Mirabegron 50 MG is also known as Tamsulosin 0.4 mg, Placebo, Myrbertiq, Hibero, Myrbetriq.

What development phase is Mirabegron 50 MG in?

Mirabegron 50 MG is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing